RDY’s earliest US-launch date is undisclosed, but it’s later than the Mar 2022 launch date for Natco, the first generic-drug company to settle with BMY on the Revlimid patent.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.